Management of Cancer-Associated Thrombosis: An Evolving Area
The management of cancer-associated thrombosis (CAT) is an evolving area. With the use of direct oral anticoagulants as a new option in the management of CAT, clinicians now face several choices for the individual cancer patient with venous thromboembolism. A personalized approach, matching the righ...
Main Authors: | Corinne Frere, Jean M. Connors, Dominique Farge |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/2999 |
Similar Items
-
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
by: Corinne Frere, et al.
Published: (2019-01-01) -
Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented
by: Dominique Farge, et al.
Published: (2020-03-01) -
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
by: Hanny Al-Samkari, et al.
Published: (2018-08-01) -
Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
by: Kaidireyahan Wumaier, et al.
Published: (2021-09-01) -
Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
by: Frits I. Mulder, et al.
Published: (2020-02-01)